P

Assignee

INTERMUNE INC

US40 patents

Top patents by PatentIndex Score

US7491794B2Feb 17, 2009

Macrocyclic compounds as inhibitors of viral replication

INTERMUNE INC147 citations97
US7728013B2Jun 1, 2010

Method of modulating stress-activated protein kinase system

INTERMUNE INC40 citations95
US7767700B2Aug 3, 2010

Method of providing pirfenidone therapy to a patient

INTERMUNE INC26 citations92
US7829665B2Nov 9, 2010

Macrocyclic inhibitors of hepatitis C virus replication

INTERMUNE INC27 citations91
US7816383B1Oct 19, 2010

Methods of administering pirfenidone therapy

INTERMUNE INC27 citations91
US7635707B1Dec 22, 2009

Pirfenidone treatment for patients with atypical liver function

INTERMUNE INC15 citations91
US7566729B1Jul 28, 2009

Modifying pirfenidone treatment for patients with atypical liver function

INTERMUNE INC37 citations91
US7696236B2Apr 13, 2010

Method of providing pirfenidone therapy to a patient

INTERMUNE INC32 citations88
US7407973B2Aug 5, 2008

Use of pirfenidone in therapeutic regimens

INTERMUNE INC36 citations88
US8013002B2Sep 6, 2011

Methods of administering pirfenidone therapy

INTERMUNE INC9 citations83
US7910610B1Mar 22, 2011

Methods of administering pirfenidone therapy

INTERMUNE INC10 citations83
US10376497B2Aug 13, 2019

Anti-fibrotic pyridinones

INTERMUNE INC5 citations82
US9675593B2Jun 13, 2017

Anti-fibrotic pyridinones

INTERMUNE INC10 citations82
US9359379B2Jun 7, 2016

Anti-fibrotic pyridinones

INTERMUNE INC12 citations82
US8969347B2Mar 3, 2015

Compounds and methods for treating inflammatory and fibrotic disorders

INTERMUNE INC10 citations82
US9290450B2Mar 22, 2016

Compounds and methods for treating inflammatory and fibrotic disorders

INTERMUNE INC5 citations81
US8753679B2Jun 17, 2014

Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

INTERMUNE INC4 citations81
US8383150B2Feb 26, 2013

Granulate formulation of pirfenidone and pharmaceutically acceptable excipients

INTERMUNE INC9 citations81
US7988994B2Aug 2, 2011

Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

INTERMUNE INC10 citations81
US7767225B2Aug 3, 2010

Capsule formulation of pirfenidone and pharmaceutically acceptable excipients

INTERMUNE INC11 citations81
US7781474B2Aug 24, 2010

Inhibitors of hepatitis C virus replication

INTERMUNE INC7 citations72
US10898474B2Jan 26, 2021

Anti-fibrotic pyridinones

INTERMUNE INC1 citations71
US10233195B2Mar 19, 2019

Anti-fibrotic pyridinones

INTERMUNE INC4 citations71
US9561217B2Feb 7, 2017

Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone

INTERMUNE INC2 citations71
US8778947B2Jul 15, 2014

Methods of administering pirfenidone therapy

INTERMUNE INC5 citations69
US9527816B2Dec 27, 2016

Method of modulating stress-activated protein kinase system

INTERMUNE INC1 citations61
US7638488B2Dec 29, 2009

Use of alpha-glucosidase inhibitors to treat alphavirus infections

INTERMUNE INC3 citations61
US9017722B2Apr 28, 2015

Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone

INTERMUNE INC2 citations60
US8048862B2Nov 1, 2011

Macrocyclic inhibitors of hepatitis C virus replication

INTERMUNE INC3 citations60
US6936695B1Aug 30, 2005

Manufacture and expression of large structural genes

INTERMUNE INC2 citations59
US6936694B1Aug 30, 2005

Manufacture and expression of large structural genes

INTERMUNE INC2 citations59
US10544161B2Jan 28, 2020

Anti-fibrotic pyridinones

INTERMUNE INC0 citations50
USRE47142ENov 27, 2018

Compounds and methods for treating inflammatory and fibrotic disorders

INTERMUNE INC0 citations50
US10010536B2Jul 3, 2018

Method of modulating stress-activated protein kinase system

INTERMUNE INC0 citations50
US7932267B2Apr 26, 2011

Use of α-glucosidase inhibitors to treat alphavirus infections

INTERMUNE INC1 citations50
US9682071B2Jun 20, 2017

Methods of improving microvascular integrity

INTERMUNE INC0 citations48
US7932277B2Apr 26, 2011

Peptide inhibitors of hepatitis C virus replication

INTERMUNE INC2 citations48
USRE39821ESep 4, 2007

Manufacture and expression of large structural genes

INTERMUNE INC0 citations48
US6939947B2Sep 6, 2005

N1-modified glycopeptides

INTERMUNE INC0 citations48
US9726677B2Aug 8, 2017

Proteomic IPF markers

INTERMUNE INC0 citations28